Why Indian HIS and EMR Platforms Need an Oncology AI Layer
India's HIS Market Is Booming. Clinical Intelligence Is Not.
India's electronic health records market reached USD 671 million in 2024 and is growing at 8.18% CAGR toward USD 1.44 billion by 2033. The Ayushman Bharat Digital Mission has accelerated adoption dramatically, integrating health records across more than 230,000 health facilities and registering over 285,000 healthcare providers. NABH has released new certification standards for HIS and EMR systems. The market is moving fast.
But if you are an HIS vendor in India—whether you are Practo, HealthPlix, EkaCare, IQVIA, DocPulse, or building a custom solution for a hospital chain—you have likely noticed a shift in what hospital buyers are asking for. Five years ago, the question was: "Can your system manage our patient data and billing?" Today, especially from hospitals with growing oncology departments, the question is: "Can your system help our oncologists make better clinical decisions?"
That is a fundamentally different question, and most HIS platforms are not equipped to answer it.
Why Oncology Creates the Biggest Gap
Not every medical specialty needs AI-powered clinical decision support with equal urgency. Oncology stands apart for specific, measurable reasons.
The evidence base is vast and changes rapidly. NCCN guidelines alone are updated multiple times per year across dozens of cancer types. New targeted therapies and biomarkers are validated continuously. Treatment decisions involve an unusually high number of variables: staging data (which has grown more complex with molecular overlays), biomarker profiles, drug interactions across multi-drug regimens, comorbidities, and treatment history.
A standard HIS stores all of this data. What it cannot do is synthesize that data against current guidelines and present actionable intelligence to the treating oncologist. That gap—between storing data and interpreting data—is what an AI layer fills.
What an AI Layer Actually Means for Your Platform
An AI layer is not a rewrite of your system. It is an extension that adds clinical intelligence to the clinical data you already manage.
In practical terms, when a physician opens a patient's record in your HIS, the AI layer simultaneously cross-references the patient's clinical data against current treatment guidelines, drug interaction databases, biomarker interpretation frameworks, and relevant clinical literature. The physician sees not just what the patient's data says, but what the current evidence suggests should happen next.
Technical Integration
For HIS vendors evaluating AI partnerships, the architecture is straightforward. The AI layer needs read access to relevant clinical data fields through standard FHIR APIs or similar interoperability frameworks that ABDM compliance already requires. It processes this data to generate clinical intelligence but does not store patient data outside the hospital's existing infrastructure—fully compliant with DPDPA 2023 requirements.
Display integration can be achieved through embedded widgets, API-driven panels, or sidebar interfaces within your existing HIS UI. The goal is minimal disruption to your platform while adding a capability your competitors probably do not have.
What OneRx Offers as an Integration Partner
OneRx is an oncology-specific clinical intelligence platform that can function as this AI layer. Its modules—Treatment Planning, Cancer Staging, Biomarker Interpretation, Drug Interactions, Clinical Guidelines, and Evidence Intelligence—are built for the exact use case hospital buyers are asking about. OneRx is available on mobile and web, designed for the Indian clinical context, and built to integrate rather than replace.
For an HIS vendor, partnering with a platform like OneRx means you can offer oncology clinical decision support without having to build deep domain expertise in oncology evidence, guideline curation, and drug interaction databases—capabilities that take years and significant investment to develop internally.
The Competitive Advantage for HIS Vendors
The Indian HIS market is getting crowded. ABDM compliance and basic EMR functionality are becoming table stakes. Differentiation has to come from somewhere. Clinical intelligence—especially in high-value, high-complexity specialties like oncology—is that somewhere.
Hospital chains are expanding their oncology services. Apollo has 13 cancer centres. Max Healthcare earns 25% of inpatient revenue from oncology. Fortis's oncology contribution is outpacing cardiology. When these hospitals evaluate HIS vendors, the ones that can offer integrated oncology clinical decision support will win the deal. The ones that cannot will be competing on price.
Build vs. Partner
Building clinical AI in-house is appealing in theory but challenging in practice. It requires oncology domain expertise (not just engineering talent), continuous evidence curation, regulatory understanding, and clinical validation. That is a multi-year, multi-crore investment with no guarantee of clinical credibility.
Partnering with a platform that has already solved these problems is faster, lower risk, and more clinically credible. You retain control of the core HIS and the customer relationship. The AI partner contributes the clinical intelligence layer. The hospital gets a better product without either party building capabilities outside their core competency.
Where This Is Headed
India's NABH has released draft certification standards for HIS/EMR systems that align with the National Health Authority's evaluation framework. The EY-CII HealthTech Survey 2025 confirms rising adoption of HIS and cloud platforms, with priorities including increased EMR use and secure data systems supported by ABDM and DPDPA.
Clinical intelligence is not a future feature. It is a current expectation. Hospital buyers are asking for it today. The HIS vendors that deliver it will define the next generation of healthcare IT in India. The ones that do not will be explaining why they cannot.